KPRX
Price
$2.75
Change
-$0.06 (-2.14%)
Updated
Oct 3 closing price
Capitalization
9.44M
VRDN
Price
$21.65
Change
+$0.43 (+2.03%)
Updated
Oct 3 closing price
Capitalization
1.77B
44 days until earnings call
Interact to see
Advertisement

KPRX vs VRDN

Header iconKPRX vs VRDN Comparison
Open Charts KPRX vs VRDNBanner chart's image
Kiora Pharmaceuticals
Price$2.75
Change-$0.06 (-2.14%)
Volume$36.23K
Capitalization9.44M
Viridian Therapeutics
Price$21.65
Change+$0.43 (+2.03%)
Volume$564.86K
Capitalization1.77B
KPRX vs VRDN Comparison Chart in %
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KPRX vs. VRDN commentary
Oct 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KPRX is a Hold and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 05, 2025
Stock price -- (KPRX: $2.75 vs. VRDN: $21.65)
Brand notoriety: KPRX and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KPRX: 64% vs. VRDN: 72%
Market capitalization -- KPRX: $9.44M vs. VRDN: $1.77B
KPRX [@Biotechnology] is valued at $9.44M. VRDN’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KPRX’s FA Score shows that 2 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • KPRX’s FA Score: 2 green, 3 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, KPRX is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KPRX’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • KPRX’s TA Score: 5 bullish, 4 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KPRX is a better buy in the short-term than VRDN.

Price Growth

KPRX (@Biotechnology) experienced а +5.36% price change this week, while VRDN (@Biotechnology) price change was +7.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.77B) has a higher market cap than KPRX($9.44M). VRDN YTD gains are higher at: 12.937 vs. KPRX (-16.667). KPRX has higher annual earnings (EBITDA): -9.41M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. KPRX (20.7M). KPRX has less debt than VRDN: KPRX (430K) vs VRDN (21.3M). VRDN has higher revenues than KPRX: VRDN (305K) vs KPRX (0).
KPRXVRDNKPRX / VRDN
Capitalization9.44M1.77B1%
EBITDA-9.41M-340.62M3%
Gain YTD-16.66712.937-129%
P/E Ratio3.67N/A-
Revenue0305K-
Total Cash20.7M563M4%
Total Debt430K21.3M2%
FUNDAMENTALS RATINGS
KPRX vs VRDN: Fundamental Ratings
KPRX
VRDN
OUTLOOK RATING
1..100
969
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6141
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KPRX's Valuation (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that KPRX’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as KPRX (100) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to KPRX’s over the last 12 months.

KPRX's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as VRDN (99) in the Biotechnology industry. This means that KPRX’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (41) in the Biotechnology industry is in the same range as KPRX (61) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to KPRX’s over the last 12 months.

KPRX's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for VRDN (100) in the Biotechnology industry. This means that KPRX’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KPRXVRDN
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNPR99.392.18
+2.24%
Monopar Therapeutics Inc
SPRO2.050.02
+0.99%
Spero Therapeutics
SUPN48.350.39
+0.81%
Supernus Pharmaceuticals
SNA347.42-1.71
-0.49%
Snap-on
ERNA1.20-0.02
-1.65%
Ernexa Therapeutics Inc

KPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, KPRX has been loosely correlated with CGEN. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if KPRX jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KPRX
1D Price
Change %
KPRX100%
-2.14%
CGEN - KPRX
33%
Loosely correlated
-7.39%
ELVN - KPRX
32%
Poorly correlated
-1.56%
SYRE - KPRX
32%
Poorly correlated
-0.56%
ABVX - KPRX
31%
Poorly correlated
+1.27%
VRDN - KPRX
31%
Poorly correlated
+2.03%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+2.03%
SYRE - VRDN
58%
Loosely correlated
-0.56%
NUVL - VRDN
56%
Loosely correlated
+0.43%
CRNX - VRDN
52%
Loosely correlated
-1.57%
NRIX - VRDN
52%
Loosely correlated
+3.30%
BEAM - VRDN
51%
Loosely correlated
+0.63%
More